Pretax income is the income that a company earns before paying income taxes. Sagimet Biosciences's pretax income for the
three
months ended in Mar. 2026 was €-9.21 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was €-37.39 Mil.
Sagimet Biosciences's pretax margin was %.
During the past 7 years, Sagimet Biosciences's highest Pretax Margin was -1393.80%. The lowest was -1393.80%. And the median was -1393.80%.
Sagimet Biosciences (STU:0O2) Pre-Tax Income Explanation
Sagimet Biosciences's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as
During the past 7 years, Sagimet Biosciences's highest Pretax Margin was -1393.80%. The lowest was -1393.80%. And the median was -1393.80%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences Pre-Tax Income Related Terms
Sagimet Biosciences Pre-Tax Income Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs NGNE, UPB, STTK: Pre-Tax Income Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Pre-Tax Income vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Pre-Tax Income falls into.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-37.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Pre-Tax Income of €-37.39 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Pre-Tax Income too high?
Sagimet Biosciences' current Pre-Tax Income is €-37.39 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Pre-Tax Income compare to NGNE and UPB?
Sagimet Biosciences' Pre-Tax Income of €-37.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Biotechnology company?
A good Pre-Tax Income depends on the Biotechnology industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Pre-Tax Income is €-37.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Pre-Tax Income of €-37.39 Mil. The current Pre-Tax Income is €-37.39 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Pre-Tax Income is €-37.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Pre-Tax Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
